TARDBP and frontotemporal dementia: CK1δ inhibitors have been proposed to inhibit the phosphorylation of TDP-43, a pathological hallmark of central nervous system (CNS) diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia [33, 34].